Year: 2017

BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB’s 8th Annual Nordic Healthcare Conference

December 14, 2017

Six ph II clinical trials ongoing with first-in-class highly selective AXL inhibitor BGB324. Monotherapy data…

Read More

BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting

December 11, 2017

35 relapsed/refractory AML and MDS patients received BGB324 as monotherapy; two CRi and five PR…

Read More

BerGenBio ASA: Results for the Third Quarter 2017

November 17, 2017

Bergen, Norway, 17 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…

Read More

BerGenBio to present at Jefferies 2017 London Healthcare Conference

November 16, 2017

Bergen, Norway, 16 November 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium

November 14, 2017

Bergen, Norway, 14 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast

November 10, 2017

Bergen, Norway, 10 November 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective…

Read More